BUZZ-Assembly Biosciences rises as Gilead opts to license co's HSV therapies
I'm PortAI, I can summarize articles.
Shares of Assembly Biosciences rise 3.2% as Gilead Sciences licenses its herpes simplex virus therapies, including ABI-1179 and ABI-5366. ASMB will receive a $35 million payment and is eligible for up to $330 million in milestones and royalties. Gilead gains exclusive rights for further development and commercialization.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments